C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Pirfenidone On Breathlessness As Measured By The Ucsd-Sobq Score In Patients With Idiopathic Pulmonary Fibrosis (ipf) With Moderate Lung Function Impairment

In a previous analysis of patients with limited vs more advanced lung function impairment, increases in University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) scores were more pronounced in patients with GAP stage II/III vs GAP stage I and in patients with baseline FVC < 80% vs FVC > 80% (Albera et al., EurRespir J., 2016). Evaluation of categorical change for patients with GAP stage II/III demonstrated that pirfenidone reduced the proportion of patients with UCSD-SOBQ score increases of > 15 points (45.6% vs 38.4%; P = 0.0449) and > 20 points (37.7% vs 28.6%; P = 0.0089) at 12 months compared with placebo; increases of > 5 or > 10 points were similar between treatment groups.